Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ...

To know whether you have narcolepsy, it's important to recognize a few common symptoms, such as excessive daytime sleepiness. Here's how.

̶ Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation ̶ ̶ Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Poster ...

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton ...

In late September 2025, RBC Capital upgraded Alkermes following promising phase 2 results for its drug candidate alixorexton in narcolepsy type 1, which showed clinically meaningful efficacy and ...

DUBLIN, April 9, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof ...

DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy ...